Rabbit Recombinant Monoclonal RUNX2 antibody - conjugated to PE.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 98% PBS, 1% BSA
| Application | Reactivity | Dilution info | Notes |
|---|---|---|---|
Application Target Binding Affinity | Reactivity Expected | Dilution info - | Notes - |
Application Antibody Labelling | Reactivity Expected | Dilution info - | Notes - |
Transcription factor involved in osteoblastic differentiation and skeletal morphogenesis (PubMed:28505335, PubMed:28703881, PubMed:28738062). Essential for the maturation of osteoblasts and both intramembranous and endochondral ossification. CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, osteocalcin, osteopontin, bone sialoprotein, alpha 1(I) collagen, LCK, IL-3 and GM-CSF promoters. In osteoblasts, supports transcription activation: synergizes with SPEN/MINT to enhance FGFR2-mediated activation of the osteocalcin FGF-responsive element (OCFRE) (By similarity). Inhibits KAT6B-dependent transcriptional activation.
AML3, CBFA1, OSF2, PEBP2A, RUNX2, Runt-related transcription factor 2, Acute myeloid leukemia 3 protein, Core-binding factor subunit alpha-1, Oncogene AML-3, Osteoblast-specific transcription factor 2, Polyomavirus enhancer-binding protein 2 alpha A subunit, SL3-3 enhancer factor 1 alpha A subunit, SL3/AKV core-binding factor alpha A subunit, CBF-alpha-1, OSF-2, PEA2-alpha A, PEBP2-alpha A
Rabbit Recombinant Monoclonal RUNX2 antibody - conjugated to PE.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 98% PBS, 1% BSA
ab236639 is not recommended for mouse IHC.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for the Abcam trial program.
RUNX2 also known as core-binding factor subunit alpha-1 (CBFA1) is a transcription factor with a molecular weight of approximately 56 kDa. It plays a pivotal role in regulating osteoblast differentiation and skeletal morphogenesis. This protein resides mainly in the nucleus and shows a high expression in bone tissue. RUNX2 binds to DNA sequences to control transcription of genes essential for bone development and maturation. The protein also possesses a Runt-homology domain enabling it to attach to specific DNA sequences.
This protein orchestrates bone formation by influencing the expression of genes involved in osteoblast differentiation. RUNX2 operates as part of the larger transcriptional complex that includes other proteins that modulate its activity. It maintains bone homeostasis by regulating the expression of osteogenic markers including bone sialoprotein and osteocalcin. The ability of RUNX2 to drive osteoblast lineage commitment highlights its importance in skeletal health and development.
RUNX2 shows significant involvement in both the Wnt signaling and TGF-beta signaling pathways. Within the Wnt signaling pathway RUNX2 interacts with beta-catenin to facilitate osteoblastogenesis and support bone matrix deposition. In the TGF-beta signaling pathway RUNX2 modulates Smad-dependent transcriptional activity important for extracellular matrix production and bone remodeling. These interactions illustrate RUNX2's central role in mediating bone development and maintenance.
RUNX2 mutations and dysregulation link to cleidocranial dysplasia a condition characterized by delayed closure of sutures in the skull and other skeletal anomalies. Additionally RUNX2 is related to osteosarcoma a type of bone cancer where its abnormal expression often contributes to tumor progression. In these contexts RUNX2 interacts with proteins like p53 an important regulator of cell cycle highlighting its influence on tumor suppressor networks and osteogenic pathways.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com